Clinical Trial Update: Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the antibody response to the 13-valent pneumococcal conjugate vaccine (PCV13) 24 months after the toddler dose; results were posted fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: 13-valent Pneumococcal Vaccine, Immunization | Phase 3 | Status: COMPLETED | Results posted: 2012-02-08